No Data
Soligenix Announces Analysis From Protocol HPN-CTCL-04
Express News | Soligenix Announced That Analysis Of The Post-treatment Data From The Open-label Study Comparing HyBryte (Synthetic Hypericin) To Valchlor (Mechlorethamine) Has Demonstrated Continued Improvement In HyBryte-treated Patients And Their Individual...
Express News | Soligenix Inc: Hybryte Was Well Tolerated in All Patients
Express News | Soligenix: 1 Of 5 Patients Receiving Valchlor Had to Be Withdrawn From Trial Due to a Clinically Significant Allergic Contact Dermatitis
Express News | Hybryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024
No Data
No Data
